Nutritional Rehabilitation in Chronic Obstructive Pulmonary Disease (COPD) Patients With Muscle Atrophy

Overview

To study in clinically stable Chronic Obstructive Pulmonary Disease (COPD) patients with muscle atrophy: 1. The short-term effects of 4 months exercise training including nutritional supplementation versus exercise training alone on physical functioning (skeletal muscle strength and exercise capacity) and body composition. 2. The long-term effects of 4 months of exercise training and nutritional supplementation followed by 8 months of nutritional counseling (with supplementation on advice) and feedback on physical activity level versus 4 months of exercise training and 8 months with feedback on physical activity level alone on physical functioning, body composition and cardiometabolic risk profile; 3. The cost-effectiveness of exercise rehabilitation and nutritional intervention versus exercise rehabilitation alone.

Full Title of Study: “Cost Effectiveness Analysis and Clinical Outcome of Nutritional Rehabilitation on Physical Functioning and Cardiometabolic Risk Profile in COPD Patients With Muscle Atrophy”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Triple (Participant, Investigator, Outcomes Assessor)
  • Study Primary Completion Date: June 2015

Detailed Description

Rationale. Recent guidelines state that pulmonary rehabilitation should be part of integrated care of patients with COPD and not limited to end stage disease. The investigators hypothesize that clinically stable COPD patients muscle atrophy, irrespective of the severity of airflow obstruction, show more pronounced long-term improvement in physical functioning and cardiometabolic risk profile after a rehabilitation programme including nutritional intervention (supplementation and counseling) than after a pulmonary rehabilitation programme without nutritional intervention, at acceptable costs. Nutritional supplementation focuses on enhancing the efficacy of the exercise training. Nutritional counseling aims at maintaining energy balance and modulating cardiovascular disease risk. Study design. The research aims will be addressed in a multi-centre, randomized, clinical trial. Phase A, Rehabilitation (4 months): – Group 1: Supervised exercise training and 3 placebo nutritional supplements daily – Group 2: Supervised exercise training and 3 nutritional supplements daily Phase B, Maintenance (8 months): – Group 1: Exercise counseling (2x) – Group 2: Exercise counseling (2x), nutritional counseling (5x) (and 1 nutritional supplement a day on indication) Phase C, Follow-up (3 months): – Group 1: no intervention – Group 2: 1 nutritional supplement a day on request Nature and extent of the burden and risks associated with participation and benefits. This study aims to tailor pulmonary rehabilitation. Participants of group 1 are visiting their rehabilitation centre 3 times for study related measurements within 15 months (2 times feedback on physical activity, 1 measurement visit). Participants of group 2 will be asked to visit their rehabilitation centre for 6 times (1 measurement visit, 3 times nutritional counseling, 1 time for feedback on physical activity, 1 time for nutritional counseling and feedback on physical activity combined) within 15 months. For both groups baseline measurements and outcome measurements after rehabilitation are already included in the CIRO rehabilitation programme.

Interventions

  • Dietary Supplement: Dietary supplementation
    • Phase A, Rehabilitation (4 months): 3 nutritional supplements daily Phase B, Maintenance (8 months): nutritional supplementation on advice (1 supplement daily) Phase C, Follow-up (3 months): no supplementation
  • Dietary Supplement: Placebo supplement
    • Phase A, Rehabilitation (4 months): 3 placebo nutritional supplements daily Phase B, Maintenance (8 months): No supplementation Phase C, Follow-up (3 months): No supplementation
  • Behavioral: Nutritional counselling
    • Phase A, Rehabilitation (4 months): No counselling Phase B, Maintenance (8 months): Nutritional counselling (4x) Phase C, Follow-up (3 months): No counselling Aim: Optimising dietary intake to physical activity pattern and energy expenditure. Minimize deterioration of dietary intake during acute exacerbations. Optimize dietary lipid profile with respect to total fat intake; trans fatty acids and proportion of poly-unsaturated fatty acids to modulate cardiovascular risk and muscle fatty acid metabolism. Increasing adherence/compliance by addressing issues like taste fatigue, gastro-intestinal symptoms, individual preferences and lifestyle.
  • Behavioral: Feedback on physical activity level
    • Phase A, Rehabilitation (4 months): No exercise counselling Phase B, Maintenance (8 months): Exercise counselling (2x) Phase C, Follow-up (3 months): No exercise counselling Aim: Integration of exercise behaviour into daily routine Improvement of self-regulation skills (e.g. self-monitoring, goal setting, action planning) Increasing adherence/compliance by addressing issues like coping with difficult situation, individual preferences and lifestyle

Arms, Groups and Cohorts

  • Placebo Comparator: Group 1 (placebo control)
    • 60 clinically stable COPD patients with muscle atrophy, eligible for out-patient pulmonary rehabilitation
  • Experimental: Group 2 (nutritional intervention)
    • 60 clinically stable COPD patients with muscle atrophy, eligible for out-patient pulmonary rehabilitation

Clinical Trial Outcome Measures

Primary Measures

  • Skeletal muscle strength
    • Time Frame: 0, 12 months
    • Skeletal muscle strength assessed by isokinetic dynamometry (Biodex®)

Secondary Measures

  • Cardiometabolic risk profile
    • Time Frame: 0, 4, 12 months
    • lipid profile (blood) systemic inflammatory profile (blood) blood pressure(hematometer) HOMA index (blood) visceral fat mass (DEXA) AGEs skin (AGE reader)
  • Health related quality of life
    • Time Frame: 0, 4, 12, 15 months
    • Assessed by: SGRQ: Saint George Respiratory Questionnaire SF36: Short Form – 36 EQ5D: EuroQol 5 domains, extended with energy/fatique domain
  • Dyspnoea
    • Time Frame: 0, 4, 12, 15 months
    • Assessed by: -MRC-index: Medical Research Council dyspnoea scale
  • Body composition
    • Time Frame: 0, 4, 12 months
    • Assessed by – DEXA scan
  • Exercise capacity
    • Time Frame: 0, 4, 12 months
    • Assessed by: – Constant Work Rate Test (CWRT)
  • Plasma levels of supplemented (micro)nutrients
    • Time Frame: 0, 4, 12 months
    • Assessed by: Plasma amino acids (leucine) Vitamin D (plasma calcidiol 25(OH)D )
  • Bone mass density
    • Time Frame: 0, 4, 12 months
    • Assessed by: – DEXA scan
  • Physical activity
    • Time Frame: 0, 4, 12, 15 months
    • Assessed by: – Accelerometry

Participating in This Clinical Trial

Inclusion Criteria

  • Chronic Obstructive Pulmonary Disease – Muscle atrophy (a FFMI under the sex- and age-specific 25th percentile FFMI values, assessed by DEXA) – Eligible for pulmonary rehabilitation Exclusion Criteria:

  • COPD patients under the age of 18; – Allergy or intolerance to fish, milk or other components of the study product; – Investigator's uncertainty about the willingness or ability of the patient to comply with the protocol requirements; – Not able to stop current supplement use or if total use will be above safe upper limits; – Participation in any other study involving investigational or marketed products concomitantly or within two weeks prior to entry into the study; – Pregnancy; – Life threatening diseases like tuberculosis, carcinoma, AIDS (including HIV+), acute leukaemia etc.

Gender Eligibility: All

Minimum Age: N/A

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Maastricht University Medical Center
  • Collaborator
    • The Netherlands Asthma Foundation
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Annemie Schols, Prof., Study Director, Maastricht UMC+ / NUTRIM, Respiratory Medicine
    • Maureen Rutten, Dr., Principal Investigator, Erasmus Medical Centre, Institute for Medical Technology Assessment
    • Emiel FM Wouters, Prof., Principal Investigator, Maastricht UMC+ and CIRO, Respiratory Medicine

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.